The National Institute for Health and Care Excellence (NICE) has confirmed that erenumab can be prescribed for migraine prevention free of charge on the National Health Service (NHS) in England and Wales.
Physicians may consider erenumab 140 mg as an option for migraine prevention in adults who have four or more migraine days a month and have failed on at least three previous preventive drugs. Treatment should be stopped after 12 weeks if it does not reduce episodic migraine by at least 50% or chronic migraine by at least 30%.
Erenumab is already available on the NHS in Scotland.
Reference
National Institute for Health and Care Excellence. Erenumab for preventing migraine (TA682). March 2021
